API Market Outlook: Downcycle Persists Amid Structural Shift

On June 2, 2026, China's drug regulator issued a draft notice introducing priority review procedures for selected chemical active pharmaceutical ingredients (APIs), underscoring a market that continues to operate under a prolonged downcycle driven by global supply-demand imbalance, even as structural shifts begin to emerge.

Supply-Demand Imbalance Keeps Industry In Prolonged Downcycle

The most fundamental characteristic of the global API market remains a cyclical downturn driven by supply-demand imbalance. China accounts for roughly one-third of global API supply, but following the surge in demand and pricing during the COVID-19 period, the sector is undergoing a prolonged adjustment phase.

Demand normalization, simultaneous capacity expansion, and homogenized competition have combined to push a wide range of API products into sustained price declines and weak industry sentiment.

Competitive dynamics have also fundamentally shifted. According to a vice president of Hisun Pharmaceutical, competition has moved from a "first launch" strategy to a "last out wins" environment, reflecting an increasingly zero-sum market structure. While some mature API products previously benefited from early-cycle margins, intensified entry and severe overcapacity have pushed many into end-of-lifecycle conditions.

Among 63 listed companies tracked by CITIC Securities' API sector coverage, 36 reported year-on-year revenue growth in Q1 2026, while 27 saw declines. On the profitability side, 30 firms posted growth in non-GAAP net profit attributable to shareholders, while 33 declined. The sector remains in a bottoming phase, though conditions are gradually shifting toward structural recovery rather than broad-based pressure.

Price Divergence Expands Across API Categories

Despite overall weakness, price trends across API categories have become increasingly differentiated.

Antibiotic chains have shown early stabilization. Prices for intermediates such as 6-APA and penicillin industrial salt have rebounded from trough levels, while downstream products including amoxicillin and ampicillin are also showing stabilization signals. Penicillin-related intermediates are widely considered among the earliest candidates for structural change in 2026.

Vitamins have entered a rising price cycle. Driven by geopolitical tensions and higher crude oil prices, major producers have suspended quotations and contracts, pushing vitamin A and vitamin E prices higher. Vitamin E, niacin (B3), and folic acid (B9) have already begun rising, with vitamin A and calcium pantothenate expected to follow.

Animal health APIs have fallen to historical lows. Prices for florfenicol have dropped from 400–700 yuan/kg to 100–200 yuan/kg, while doxycycline has also reached historic trough levels, resulting in sustained losses for some producers. However, accelerated industry consolidation suggests a cyclical recovery could emerge in 2026.

Sartan and heparin products are also at depressed levels. Sartans have largely bottomed after years of price erosion, while Huahai Pharmaceutical noted potential short-term price recovery in products such as losartan potassium and irbesartan due to rising upstream chemical and energy costs. Heparin APIs remain in a prolonged oversupply equilibrium following their 2019–2021 peak cycle.

Overall, Q1 2026 data indicates continued year-on-year pressure across traditional APIs, though select categories are beginning to show sequential recovery.

Rising Cost Pressure Transmits Through Supply Chain

Cost inflation has become a key variable shaping API market dynamics. Elevated crude oil prices, combined with geopolitical risks including those around the Strait of Hormuz, have pushed upstream chemical input costs higher, with transmission effects gradually reaching downstream producers.

While China's API producer price index continues to decline, upstream raw material costs are showing clear upward momentum.

This transmission mechanism is contributing to selective price recovery. In antibiotics, stabilization is partly attributed to higher base chemical and energy costs. For export-oriented intermediates such as 6-APA, concentrated supply and stronger pricing power among Chinese producers have enabled partial cost pass-through.

Policy Environment Combines Domestic Support With External Barriers

In China, regulatory reform is offering procedural advantages. The priority review draft issued on June 2, 2026, outlines three categories of APIs eligible for expedited review, including those linked to urgently needed drug formulations. Certain shortage drugs may be directly included in priority review without application or public notice, aiming to shorten approval timelines and improve supply efficiency.

Environmental and safety regulations, alongside the marketing authorization holder (MAH) system and linked review mechanisms, continue to accelerate industry consolidation. CR10 concentration rose from 12% in 2019 to 18% in 2025.

Internationally, three major markets are reshaping supply chains and increasing trade barriers. India continues to expand domestic API capacity under its production-linked incentive (PLI) program, approving 48 projects covering 25 APIs and intermediates as of December 2024. In January 2026, India imposed minimum import price restrictions on penicillin G potassium salt, 6-APA, and amoxicillin for one year.

The European Union is advancing its Critical Medicines Act, aimed at strengthening supply security and local manufacturing for around 270 essential medicines, potentially raising barriers for non-EU generic and API imports.

The United States is pursuing pharmaceutical reshoring through a combination of Section 232 investigations, differentiated tariffs, and bilateral agreements, introducing ongoing uncertainty into China-US pharmaceutical trade dynamics.

Meanwhile, currency movements are adding pressure. The renminbi's appreciation since April 2025 accelerated through 2026, with offshore RMB briefly breaking 7.0 per US dollar in late 2025 and onshore rates reaching around 6.82, a three-year high. The appreciation has already affected first-quarter 2026 earnings for multiple API exporters.

Supply Chain Restructuring And Emerging Growth Engines

Global API supply chains are undergoing accelerated realignment. India is pushing upstream localization, the EU is reinforcing domestic pharmaceutical capacity, and the US is promoting reshoring, collectively intensifying competition and policy uncertainty.

At the same time, new therapeutic areas are creating a second growth curve. GLP-1 small-molecule oral drugs, including Eli Lilly's Orforglipron, along with small interfering RNA (siRNA) therapies from Alnylam Pharmaceuticals, are expected to drive substantial new demand for APIs and intermediates by 2026.

Companies positioned within supply chains of major multinational pharmaceutical firms such as Eli Lilly and Company and Novo Nordisk may transition from cyclical chemical exposure to innovation-driven pharmaceutical value chains. However, entry barriers remain high due to long GMP certification cycles, FDA and EMA inspections, and multi-year DMF-to-PAI timelines.

Industry participants note that these structural barriers are likely to reinforce a "winner-takes-most" dynamic.

Corporate strategies are increasingly diverging. Firms with differentiated APIs, contract manufacturing (CMO) capabilities, or integrated API-to-formulation models are showing greater resilience, while commodity-heavy producers remain under pressure.

For example, Puluo Pharmaceutical reported a 18.92% year-on-year decline in API and intermediate revenue in Q1 2026, though gross margin improved by three percentage points to 16.52%. Hisun Pharmaceutical continues to position its API business as a core industrial base while increasing the share of high-value specialty and patented APIs.

Conclusion: Bottoming Cycle Meets Structural Transformation

The global API market is currently at the intersection of cyclical bottoming and structural transformation.

In the short term, the industry remains in a phase of capacity clearing and inventory digestion, with most product categories under pricing pressure and a clear inflection point yet to emerge.

In the medium term, rising upstream cost pressures, particularly in crude oil and chemical inputs, are beginning to support selective price recovery, with antibiotics and vitamins showing early stabilization while animal health, sartan, and heparin products remain near cyclical lows.

In the long term, growth from GLP-1 oral therapies and siRNA drugs, combined with China's streamlined approval framework and ongoing corporate shifts toward integrated and innovation-linked models, is reshaping both competitive structure and valuation logic.

Against this backdrop, companies with strong compliance systems, technological barriers, resilient supply chains, and forward-looking strategic positioning are best placed to emerge stronger from the ongoing industry rebalancing.